JNJ
Johnson & Johnson · Healthcare · Drug Manufacturers - General
Toutes les données de détention : gérants 13F suivis uniquement, positions en actions ordinaires, période de référence Q2 2024
| Trimestre | Détenteurs | Δ | Actions | Valeur déclarée | Nouveau | Sorties |
|---|---|---|---|---|---|---|
| Q2 2026 | 183 | +1 | 1.45B | $367.13B | +5 | −3 |
| Q1 2026 | 184 | 0 | 1.43B | $348.29B | +4 | −5 |
| Q4 2025 | 183 | 0 | 1.52B | $314.40B | +2 | −1 |
| Q3 2025 | 28 | 0 | 887.20M | $164.46B | — | −1 |
| Q2 2025 | 26 | +1 | 740.96M | $113.15B | +1 | — |
| Q1 2025 | 22 | -1 | 281.15M | $46.60B | — | −1 |
| Q4 2024 | 23 | +3 | 290.64M | $42.01B | +3 | — |
| Q3 2024 | 19 | -2 | 157.55M | $25.50B | — | −2 |
| Q2 2024 | 21 | — | 161.11M | $23.53B | — | — |
| # | Gérant | Actions | Δ actions | Valeur | Leur poids | Détenu | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passif) | 55.10M | — | $8.03B | 0.7% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passif) | 55.10M | — | $8.03B | 0.7% | n/c | 1 | SEC ↗ |
| 3 | Norges Bank ✦ (passif) | 29.09M | — | $4.25B | 0.6% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 24.91M | — | $3.64B | 0.4% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 24.91M | — | $3.64B | 0.4% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 24.85M | — | $3.63B | 0.7% | n/c | 1 | SEC ↗ |
| 13 | Fisher Asset Management ✦ | 7.01M | — | $1.02B | 0.4% | n/c | 1 | SEC ↗ |
| 14 | Marshall Wace ✦ | 3.88M | — | $567.83M | 0.8% | n/c | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 3.88M | — | $567.83M | 0.8% | n/c | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 3.35M | — | $489.18M | 0.8% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 3.35M | — | $489.18M | 0.8% | n/c | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 3.35M | — | $489.18M | 0.8% | n/c | 1 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 3.35M | — | $489.18M | 0.8% | n/c | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 3.35M | — | $489.18M | 0.8% | n/c | 1 | SEC ↗ |
| 21 | Bridgewater Associates ✦ | 3.20M | — | $468.34M | 2.4% | n/c | 1 | SEC ↗ |
| 22 | Renaissance Technologies ✦ | 1.53M | — | $223.58M | 0.4% | n/c | 1 | SEC ↗ |
| 23 | Citadel Advisors ✦ | 1.46M | — | $212.68M | 0.2% | n/c | 1 | SEC ↗ |
| 24 | Citadel Advisors ✦ | 1.46M | — | $212.68M | 0.2% | n/c | 1 | SEC ↗ |
| 25 | D. E. Shaw & Co. ✦ | 1.16M | — | $170.12M | 0.3% | n/c | 1 | SEC ↗ |
| 26 | D. E. Shaw & Co. ✦ | 1.16M | — | $170.12M | 0.3% | n/c | 1 | SEC ↗ |
| 27 | Tweedy, Browne ✦ | 1.13M | — | $165.23M | 7.6% | n/c | 1 | SEC ↗ |
| 28 | Millennium Management ✦ | 1.08M | — | $157.41M | 0.1% | n/c | 1 | SEC ↗ |
| 29 | Adage Capital Partners ✦ | 852.52K | — | $124.60M | 0.2% | n/c | 1 | SEC ↗ |
| 30 | Arrowstreet Capital ✦ | 828.12K | — | $121.04M | 0.1% | n/c | 1 | SEC ↗ |
| 31 | Two Sigma Investments ✦ | 649.75K | — | $94.97M | 0.2% | n/c | 1 | SEC ↗ |
| 32 | Markel Group ✦ | 610.80K | — | $89.27M | 0.9% | n/c | 1 | SEC ↗ |
| 33 | Markel Group ✦ | 610.80K | — | $89.27M | 0.9% | n/c | 1 | SEC ↗ |
| 34 | Gotham Asset Management ✦ | 218.02K | — | $31.87M | 0.4% | n/c | 1 | SEC ↗ |
| 35 | GAMCO Investors ✦ | 98.36K | — | $14.38M | 0.2% | n/c | 1 | SEC ↗ |
| 36 | Fairfax Financial ✦ | 73.40K | — | $10.72M | 0.9% | n/c | 1 | SEC ↗ |
| 37 | Dodge & Cox ✦ | 21.10K | — | $3.08M | 0.0% | n/c | 1 | SEC ↗ |
« Leur pondération » = la part de la position dans la valeur des actions 13F déclarées de ce gérant — la mesure de conviction. ✦ = gérant sélectionné.
Nouveaux acheteurs
| Aucun nouvel acheteur suivi ce trimestre. |
Sorti(e)
| Aucune sortie suivie ce trimestre. |
Contexte marché global: parmi TOUS les déposants 13F (données structurées SEC, Q1 2026): 1 détenteurs, 136.10K actions, $33,268 déclaré. Il s'agit d'une période différente et plus ancienne que les chiffres de l'univers suivi ci-dessus ; les deux ne sont jamais mélangés.
Ce que les détenteurs suivis de ce titre détiennent le plus souvent par ailleurs — nombre de détentions partagées, sans relation fondamentale sous-jacente.
Achats sur le marché libre (P)
Aucun achat d'initié sur le marché libre dans notre fenêtre de couverture.
Ventes sur le marché libre (S)
Officer · 15.00K act. · $3.95M
Officer, Director · 20.98K act. · $5.50M
Officer, Director · 102.31K act. · $26.70M
Les attributions, exercices et retenues fiscales ne sont jamais comptabilisés comme des achats ou des ventes ici. Méthodologie
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug to treat a…
Reuters